News Center

Home page

Peak Report

News reports

Announcement on the 2019 profit distribution plan.

Release time:

2021-05-20

Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Pro 2020-005

Zhejiang Jianfeng Group Co., Ltd.

Announcement on 2019 Profit Distribution Plan

The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .

Important Content Note:

Distribution Ratio per Share: Cash Dividend 3.0 Yuan (Tax Included) for Every 10 Shares. No bonus shares will be distributed and no CPF capitalization will be made in 2019.
This profit distribution is based on the total share capital registered on the equity registration date of the implementation of the equity distribution, and the specific date will be specified in the equity distribution implementation announcement.
If the total share capital of the company changes before the equity registration date for the implementation of the equity distribution, it is proposed to maintain the distribution ratio per share unchanged and adjust the total distribution accordingly, and the specific adjustment will be announced separately.
Brief description of this year's profit distribution plan: At present, the company is in the stage of accelerated development. In 2020, the company will accelerate the promotion of Guizhou peak daily production of 4500 tons of cement clinker new dry cement production line off-site technical transformation (with waste heat power generation) project, peak pharmaceutical Jinxi production base annual output of 2 billion pieces of solid preparation project, Anhui Zhongwang phase II technical transformation project, new Beika chemical technical transformation project and other projects under construction. In addition, Spike Pharmaceuticals has a number of new drugs in various stages of research and development, anti-tumor drug "DPT" has entered the clinical stage, the need to increase research and development investment. The development of the above-mentioned business requires large financial support. The content of

1. profit distribution plan

was audited by Tianjian Certified Public Accountants (Special General Partnership). The net profit attributable to the shareholders of the parent company in the consolidated statement of the company in 2019 was ,724,688,055.43 yuan. The net profit of the parent company's accounting statement ,267,306,832.98 yuan. According to the parent company's current net profit as the base, extract 10% statutory provident fund 26,730,683.30 yuan, plus undistributed profit 1,014,878,186.69 yuan at the beginning of the year, minus 2018 annual cash dividend 103,225,148.40 yuan, and the distributable profit for this year is 1,152,229,187.97 yuan.

Company plans to make cash distribution in 2019 , based on ,344,083, 828 shares at the end of 2019 , with cash dividends 3.0 yuan (tax included) for every 10 shares, and the total cash dividends to all shareholders registered on the date of record are 103,225,148.40 yuan (tax included).

No CPF conversion to share capital in 2019 .

If the total share capital of the Company changes due to the conversion of convertible bonds/ repurchase of shares / equity incentive grant of share repurchase and cancellation / major asset restructuring share repurchase and cancellation during the period from the date of disclosure of this announcement to the date of registration of equity distribution, the Company intends to maintain the distribution ratio per share and adjust the total distribution accordingly. If the subsequent total share capital changes, the specific adjustment will be announced separately.

This profit distribution plan still needs to be submitted to the general meeting of shareholders for consideration. During the reporting period of

, the net profit attributable to the shareholders of the listed company in the consolidated statement of the company was 724,688,055.43

yuan, the accumulated undistributed profit of the parent company was

1,152,229,187.97 yuan, and the total cash dividend to be distributed by the listed company was 103,225,148.40 yuan (including tax), the proportion of net profit attributable to shareholders of listed companies this year is lower than 30% . The specific reasons are as follows: At present, the company is in the stage of accelerated development and has many construction projects. In 2020

, the company will continue to accelerate the construction of the project

( estimated investment is 6.5 .2 billion ) of the new dry cement production line with a daily output of 4500 tons of cement clinker in Guizhou Huangping Jianfeng Cement Co., Ltd; the holding subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. Jinxi Production Base produces 20 .6 billion pieces of solid preparation project ( is expected to invest 50146 million yuan ) ; The holding subsidiary Anhui zhongwang pharmaceutical co., ltd. phase ii technological transformation project ( estimated total investment is 17500 .06 million yuan ) ; the construction and renovation of the technical renovation project ( is expected to invest 13274.25 .12 million yuan ) and other projects under construction by the end of 2019 , the above-mentioned projects have invested 4.91 .8 billion yuan. In addition, Jianfeng Pharmaceutical has a number of new drugs in various stages of research and development. The new anti-tumor drug "DPT " has entered the clinical stage. Jianfeng Pharmaceutical and its subsidiaries Zhejiang Erying Pharmaceutical Co., Ltd. and Zhejiang Jianfeng Yien Biotechnology Co., Ltd. will further increase product research and development and introduction, and need to increase research and development investment. The development of the above-mentioned business requires large financial support. 3. the decision-making procedure performed by the company

(I) the convening, deliberation and voting of the board meeting

2020

April# December August

24 , the company held the 14th meeting of the 10th board of 131 by combining on-site and communication voting. the company currently has eight directors, all of whom attended the meeting in person, comply with the relevant provisions of the "Company Law" and the "Articles of Association", and the resolutions made are legal and valid. The meeting was presided over by Chairman Jiang Xiaomeng. After deliberation and voting, the profit distribution plan of the company 2019 was deliberated and approved by 8 votes, 0 votes against, and 0 votes abstention. The board of directors of intends to submit the plan to the annual general meeting of shareholders of 2019 for deliberation. When the company holds the general meeting of shareholders, it will provide investors with convenient conditions for online voting.

(II) Independent Director's Opinion

The independent director of the company expressed the following opinions on the company's 2019

annual profit distribution plan:

, agreeing that the company will pay a cash dividend of 3.0

yuan (including tax) for every

10 shares based on 2019 year-end share capital ,344,083, 828 shares, the total amount of cash dividends distributed to all shareholders registered on the date of record is 103,225,148.40 yuan (including tax), 2019 year will not be converted into share capital. , the profit distribution plan is based on the actual operating results and financial situation of the Company

2019

, combined with the actual needs of the Company's future business development. Retained undistributed profits are mainly used to meet the capital needs of the company's development, which is conducive to the sustainable and healthy development of the company, and there is no harm to the rights and interests of shareholders, especially small and medium shareholders. The independent directors are of the opinion that the profit distribution plan complies with the relevant provisions of the Articles of Association for profit distribution and the actual operating conditions of the Company. 3 , the company's board of directors considered and approved the above profit distribution plan. The Independent Directors are of the opinion that the convening, convening and deliberation and voting procedures of this meeting are in compliance with relevant laws, regulations and the Articles of Association of the Company, and are legal and effective; and agree to submit the proposal to the Company's

2019

Annual General Meeting for consideration. (III) the opinions of the board of supervisors

2020

, the company held the 184 meeting of the 9th 183 of the 9th board of supervisors. the company currently has five supervisors, all of whom attended the meeting in person, which conforms to the relevant provisions of the company law and the articles of association, and the resolution made is legal and effective. The meeting was presided over by Mr. Chen Tianci, Chairman of the Board of Supervisors. After deliberation and voting, the company's profit distribution plan for the year 2019 was deliberated and approved with 5 votes, 0 votes against, and 0 abstentions. Agree to submit to the general meeting of shareholders for consideration. The Board of Supervisors believes that: the company's 2019 profit distribution plan complies with the relevant provisions of the Articles of Association; the description of the profit distribution plan is objective and true, the decision-making procedures are in compliance, and meet the interests of all shareholders and the company's production and operation needs; No company profit distribution and cash dividend decisions were found to damage the legitimate rights and interests of shareholders.

4. Related Risk Reminder This profit distribution plan must be submitted to the company's 2019

annual general meeting for deliberation and approval before implementation. Investors are kindly requested to pay attention to investment risks.

hereby announce

Zhejiang Jianfeng Group Co., Ltd. Board of Directors

April

28, 2002

More information

Inferior spikes do this

In the eastern corner of the production area of Jianfeng Health Technology Company, there is a very inconspicuous building. From below, only a few pipes of uneven thickness can be seen on the top and the slogan "Focus on Environmental Protection and Promote Sustainable Development" with red letters on the yellow background on the stainless steel guardrail. Walking up, you can only see several closed pools and a small room with stacks of documents, test tubes, glass bottles and other testing tools on the table. This is the peak and healthy sewage treatment station. The production sewage of the whole factory area is concentrated here. After adjustment (PH adjustment), pre-acidification, anaerobic, anoxic, aerobic (aeration), precipitation and other links, it is discharged into the pipe network after reaching the special discharge standard. Yin Zhiwu, executive deputy general manager of Jianfeng Health, said that because the sewage treatment station in Wucheng District has not yet been built, Jianfeng Health has not yet been able to achieve pipe discharge, and the relevant national laws have strict requirements on the discharge of water pollutants from the extraction pharmaceutical industry. Sewage discharge must reach a special discharge limit, that is, chemical oxygen demand (COD) must be less than 50 mg/L. Enterprise development and environmental protection are both the concept of peak health since its establishment. In March this year, on the basis of the original environmental protection facilities, Jianfeng Health carried out technical renovation of waste gas collection and treatment facilities, and at the same time installed a sealing cover on the sewage treatment station to realize the closed collection of waste gas. Since the trial operation of this facility in mid-May, the overall effect has been obvious. The original treatment tank would emit an unpleasant smell during work, but now the smell has been significantly reduced. Compared with the young enterprise of peak health, the relatively "older" peak pharmaceutical has more experience in sewage treatment and environmental protection. Akihama

2020

07-31

2016 Annual General Meeting of Shareholders

News from our newspaper On May 19, the on-site meeting of Jianfeng Group's 2016 Annual General Meeting of Shareholders was held in Conference Room 314 of Jianfeng Building to deliberate and pass the "2016 Annual Report on the Work of the Board of Directors" and other proposals. The meeting was convened by the board of directors of Jianfeng Group and chaired by Chairman Jiang Xiaomeng. A total of 6 shareholders and proxies attended the meeting, and the total number of voting shares held by them was 55,604,815, accounting for 16.16 of the total voting shares of the company. Some directors, supervisors and secretary of the board of directors of the company attended the meeting, and some senior managers attended the meeting as nonvoting delegates. The meeting was held and voted on by a combination of on-site voting and online voting, it deliberated and passed nine proposals, including the 2016 Work Report of the Board of Directors, the 2016 Work Report of the Board of Supervisors, the 2016 Financial Final Accounts Report, the 2016 Profit Distribution Proposal, the Proposal to Hire the Company's 2017 Audit Institution, the Proposal to Provide Guarantee to Holding Subsidiaries, the 2016 Annual Report and its Summary, the Election of Mr. Huang Sujian as Director of the Company and the Election of Mr. Chen Tianci as Supervisor of the Company. (Zhou Hengbin)

2020

07-31

2016 Annual General Meeting of Shareholders

2020

07-31

2016 Annual General Meeting of Shareholders

2020

07-30

Jianfeng Pharmaceutical Won Advanced Collective of Municipal Red Cross Humanitarian Promotion Award

On April 24, the Red Cross Society of Jinhua issued a circular commending the advanced units and individuals of the 2016 Red Cross Humanitarian Promotion Award. Peak Pharmaceutical Company won the Red Cross Humanitarian Promotion Award for Advanced Collective. The Red Cross is a social relief organization engaged in humanitarian work, with the purpose of carrying forward the spirit of humanity, fraternity and dedication, protecting human life and health, and promoting the cause of peace and progress of mankind. As a socially responsible enterprise, Jianfeng Pharmaceutical has always attached importance to public welfare and charity work, vigorously promoted the spirit of the Red Cross, and vigorously supported the work of the Red Cross with practical actions. In September 2016, at the theme publicity activity of "World First Aid Day" and the opening ceremony of the municipal Red Cross emergency rescue station (point), Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, donated 6 AEDs known as "life-saving artifact" to the Red Cross on behalf of Jianfeng Pharmaceutical, it is equipped with six Red Cross emergency rescue service stations (points), namely, Jinhua high-speed railway station, sports center, cultural center, Shuanglong scenic spot, Siping village scenic spot and Suoyuan village scenic spot. The configuration of AED equipment has played a very good role in improving the emergency rescue capacity of Jinhua's key locations, and has been affirmed by the Red Cross and related units. (Spike Pharmaceuticals)

2020

07-31

Jingmai Airport Test Flight Successfully Runway Cement Spike Manufacturing

On April 7, a Boeing 737-700 aircraft of China Eastern Airlines Yunnan took off from Kunming. After completing two flight test subjects, it landed safely at Lancang Jingmai Airport. This not only marked the basic completion of the airport flight area, The official start of the test flight also marked that the "Peak" brand airport runway cement passed the first "final exam". Lancang Jingmai Airport is a major project with milestone significance in the history of Pu'er transportation construction. Since then, an air corridor connecting southwest Yunnan and Southeast Asia has been added between Kunming and Pu'er, which will greatly promote the development and utilization of tourism resources in Lancang, Menglian and Ximeng "Pu'er Green Triangle" area, and promote the sustainable development of local economy and society; it is of great significance to strengthen the city's national defense construction, maintain border stability, promote national unity, improve emergency rescue capabilities, and promote Pu'er's integration into the country's "Belt and Road" construction. Since the start of the construction of the airport, Yunnan Jianfeng has been paying close attention to it, organizing technical research and repeated tests, and finally produced high-quality airport runway special cement, and with excellent product quality, superior product performance and high-quality service, it has become a runway for Lancang Airport. Cement manufacturer. This not only fills the gap of "peak" airport special cement, but also is of great significance to promote the "peak" brand and improve the market influence of enterprises. It is understood that Jingmai Airport is initially confirmed to be officially opened to traffic at the end of May. (Li Liangping)

2020

07-31

< 1...46 47 48...61 > 跳转到页